136 related articles for article (PubMed ID: 19439488)
21. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
[TBL] [Abstract][Full Text] [Related]
22. Plasma protein binding of quinine: binding to human serum albumin, alpha 1-acid glycoprotein and plasma from patients with malaria.
Wanwimolruk S; Denton JR
J Pharm Pharmacol; 1992 Oct; 44(10):806-11. PubMed ID: 1360505
[TBL] [Abstract][Full Text] [Related]
23. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
[TBL] [Abstract][Full Text] [Related]
24. Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir?
Mauss S; Schmutz G; Kuschak D
AIDS; 2002 Jan; 16(2):296-7. PubMed ID: 11807318
[No Abstract] [Full Text] [Related]
25. Serum protein binding of lerisetron, a novel specific 5HT3 antagonist, in patients with cancer.
Calvo R; Jiménez RM; Trocóniz IF; Suárez E; Gonzalo A; Lucero ML; Raczka E; Orjales A
Cancer Chemother Pharmacol; 1998; 42(5):418-22. PubMed ID: 9771958
[TBL] [Abstract][Full Text] [Related]
26. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
27. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.
Stephan C; von Hentig N; Kourbeti I; Dauer B; Mösch M; Lutz T; Klauke S; Harder S; Kurowski M; Staszewski S
AIDS; 2004 Feb; 18(3):503-8. PubMed ID: 15090803
[TBL] [Abstract][Full Text] [Related]
28. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
Wyen C; Fuhr U; Frank D; Aarnoutse RE; Klaassen T; Lazar A; Seeringer A; Doroshyenko O; Kirchheiner JC; Abdulrazik F; Schmeisser N; Lehmann C; Hein W; Schömig E; Burger DM; Fätkenheuer G; Jetter A
Clin Pharmacol Ther; 2008 Jul; 84(1):75-82. PubMed ID: 18183034
[TBL] [Abstract][Full Text] [Related]
29. Factors affecting serum protein binding of cocaine in humans.
Parker RB; Williams CL; Laizure SC; Lima JJ
J Pharmacol Exp Ther; 1995 Nov; 275(2):605-10. PubMed ID: 7473145
[TBL] [Abstract][Full Text] [Related]
30. Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil.
Vergara TR; Estrela RC; Suarez-Kurtz G; Schechter M; Cerbino-Neto J; Barroso PF
Ther Drug Monit; 2006 Apr; 28(2):175-9. PubMed ID: 16628127
[TBL] [Abstract][Full Text] [Related]
31. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy.
Estrela Rde C; Ribeiro FS; Barroso PF; Tuyama M; Gregório SP; Dias-Neto E; Struchiner CJ; Suarez-Kurtz G
Pharmacogenomics; 2009 Feb; 10(2):311-8. PubMed ID: 19207033
[TBL] [Abstract][Full Text] [Related]
32. Binding of catecholamines to alpha-1 acid glycoprotein, albumin and lipoproteins in human serum.
Sager G; Bratlid H; Little C
Biochem Pharmacol; 1987 Nov; 36(21):3607-12. PubMed ID: 3675618
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.
Lambert JS; Else LJ; Jackson V; Breiden J; Gibbons S; Dickinson L; Back DJ; Brennan M; Connor EO; Boyle N; Fleming C; Coulter-Smith S; Khoo SH
HIV Med; 2011 Mar; 12(3):166-73. PubMed ID: 20726906
[TBL] [Abstract][Full Text] [Related]
34. Binding of prazosin to alpha 1-acid glycoprotein and albumin: effect of protein purity and concentrations.
Sager G; Jaeger R; Little C
Pharmacol Toxicol; 1989 Apr; 64(4):365-8. PubMed ID: 2748545
[TBL] [Abstract][Full Text] [Related]
35. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).
Breilh D; Pellegrin I; Rouzés A; Berthoin K; Xuereb F; Budzinski H; Munck M; Fleury HJ; Saux MC; Pellegrin JL
AIDS; 2004 Jun; 18(9):1305-10. PubMed ID: 15362663
[TBL] [Abstract][Full Text] [Related]
36. Lopinavir protein binding in vivo through the 12-hour dosing interval.
Boffito M; Hoggard PG; Lindup WE; Bonora S; Sinicco A; Khoo SH; Di Perri G; Back DJ
Ther Drug Monit; 2004 Feb; 26(1):35-9. PubMed ID: 14749547
[TBL] [Abstract][Full Text] [Related]
37. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
38. A bioequivalence study comparing two formulations of lopinavir/ritonavir capsules.
Tippabhotla SK; Thudi NR; Raghuvanshi R; Khuroo AH; Gurule S; Mishra S; Monif T; Lao VK
Int J Clin Pharmacol Ther; 2008 Apr; 46(4):204-10. PubMed ID: 18397695
[TBL] [Abstract][Full Text] [Related]
39. Binding of prazosin and propranolol at variable alpha 1-acid glycoprotein and albumin concentrations.
Sager G; Jaeger R; Little C
Br J Clin Pharmacol; 1989 Feb; 27(2):229-34. PubMed ID: 2713217
[TBL] [Abstract][Full Text] [Related]
40. Binding of bupivacaine to human serum proteins, isolated albumin and isolated alpha-1-acid glycoprotein. Differences between the two enantiomers are partly due to cooperativity.
Mazoit JX; Cao LS; Samii K
J Pharmacol Exp Ther; 1996 Jan; 276(1):109-15. PubMed ID: 8558418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
